Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

th SEGA include mouth ulcers, infections of the respiratory tract, sinuses and ears and fever.

Please see full Prescribing Information for AFINITOR.

# Rapamune® (sirolimus) and Torisel® (temsirolimus) are registered trademarks of Wyeth Pharmaceuticals Inc.

About SOM230 (pasireotide)SOM230 is an investigational multireceptor targeting somatostatin analog (SSA) that binds to four of the five somatostatin receptor subtypes (sst 1, 2, 3 and 5).

Because it is an investigational compound, the tolerability and efficacy profile of SOM230 has not yet been fully established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. There is no guarantee that SOM230 will become commercially available.

Information about Novartis clinical trials for SOM230 can be obtained by healthcare professionals at www.pasporttrials.com.

Disclaimer The foregoing release contains forward-looking statements that can be identified by terminology such as "pipeline," "will," "commitment," "potential," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be submitted or approved for sale in any market, or that any new indications will be submitted or approved for existin
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Inc. today announced that the U.S. Food and Drug ... (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment ... by any diagnosed conditions of the uterus (womb), in ... With this approval, Natazia is the first and only ...
... March 14, 2012  Nile Therapeutics, Inc. (OTCQB: NLTX), ... heart failure patients, today announced the schedule of ... American College of Cardiology (ACC) 61th Scientific Session, ... Monday, March 26, 2012 Time: 10:00 AM -12:00 PM ...
Cached Medicine Technology:U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 2U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 3U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 4Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting 2
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... researchers will lead a $10.25 million effort to study ... need for dialysis. The five-year project supports research ... that, though rare, generates an enormous individual and societal ... to nearly 12 percent of cases of kidney failure, ...
... , , , ... by wearing a purple LFA wristband until there is an FDA-approved medication ... It,s been 50 years since the U.S. Food and Drug Administration (FDA) ... President! To highlight the need for safer, more tolerable, and effective medications, ...
... NEW YORK, Sept. 22 The Global Network ... partnership with the Miss Universe Organization aimed at educating millions ... control and eliminate neglected tropical diseases across the region. ... time in their home countries participating in education and mass ...
... , , SAN MARCOS, Calif., ... NAII ), a leading formulator, manufacturer and marketer of customized nutritional ... per diluted share on net sales from continuing operations of $73.9 ... fiscal 2009 results include a net loss from discontinued operations of ...
... , , NEW YORK, Sept. 22 ... of specialty insurance and insurance-related products and services, will release 2009 third ... The news release will be available on Assurant,s Web site at ... broadcast its 2009 third quarter conference call at 9:00 a.m. ET on ...
... ELM GROVE, Wis., Sept. 22 A free ... Factor in HAI , is being sponsored by Compirion Healthcare Solutions, ... Wisconsin. Dates and times, along with registration information, can be found ... webinar are the main causes of non-compliance with hospital hand-washing ...
Cached Medicine News:Health News:Kidney advocates launch $10.25 million effort to examine cause of kidney failure 2Health News:The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM) 2Health News:Miss Universe Organization, Global Network for Neglected Tropical Diseases Join Forces to Eliminate Neglected Tropical Diseases in the Americas 2Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 2Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 3Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 4Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 5Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 6Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 7Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 8Health News:Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29 2Health News:Free Webinar on Helping Hospitals Control Healthcare-Associated Infections by Improving Hand Hygiene 2Health News:Free Webinar on Helping Hospitals Control Healthcare-Associated Infections by Improving Hand Hygiene 3